BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Harnesses Blue Light, Innovative Technology for Cancer Imaging

February 4, 2021 13:15:06

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is harnessing the virtues of blue light in a health-enhancing way. By utilizing the company’s proprietary i/Blue Imaging (TM) System with a contrast agent, surgeons will be able to better visualize the parameters of cancers and develop the appropriate response strategy. Imagin is developing its platform for use in bladder cancer surgery. It relies on Cysview, a drug that rapidly infiltrates cancer cells and causes them to glow bright pink under blue light. Cysview is administered just before surgery and the blue light is used endoscopically to locate and examine the tumor. A recent article discussing this reads, “One benefit of Imagin’s technology is that it ‘addresses the limiting factors of’ current systems by making its surgical light source, video camera and data recording technology adaptable to almost any scope already on the market. The light source then displays white and blue light images side-by-side on the surgeon’s monitor without a need to toggle back and forth between one image and the other.”

To view the full article, visit https://ibn.fm/JYN7s

About Imagin Medical

Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The company believes its first product, the i/Blue(TM) Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The company’s initial focus is bladder cancer. For more information about the company, visit www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork